EurekAlert from AAAS
Home About us
Advanced Search
1-Nov-2014 07:30
Beijing Time

Username:

Password:

Register

Forgot Password?

Breaking News

Multimedia Gallery

Subscribe/Sponsor

Interviews

Events Calendar

Selected Science Sources in China

MOST

CAS

CAE

CAST

NSFC

CASS

CAAS

CAMS

RSS

EurekAlert!

Text Size Option

Language

English (英文)

Chinese (中文)

In The Spotlight


U.S. FDA approves possible Alzheimer's test

Greg Miller
ScienceNOW Daily News
April 9, 2012



Credit: Image courtesy of the National Institute on Aging/National Institutes of Health

On Friday, the U.S. Food and Drug Administration (FDA) approved a radioactive compound for evaluating people with cognitive impairment for Alzheimer's disease. The drug, called Amyvid, binds to amyloid plaques, the calling card of Alzheimer's disease in the brain. When administered before a PET scan, Amyvid allows doctors to see whether amyloid has begun to build up. A negative test reduces the likelihood that a patient's cognitive problems are due to Alzheimer's, FDA said in its approval letter, but a positive test does not necessarily confirm a diagnosis of Alzheimer's.

The compound was developed by Avid Radiopharmaceuticals, which was acquired by Eli Lilly and Company in 2010. Last year, an FDA panel decided to hold off on approving Amyvid pending more compelling evidence that different doctors would read the scans consistently. Lilly subsequently developed an online training course for neuroradiologists to ensure consistent readings.

Amyvid has been used in research, including clinical trials, for years, says Michael Weiner, a neurologist at the University of California, San Francisco, and principal investigator of the Alzheimer's Disease Neuroimaging Initiative. The compound will be a powerful tool for clinicians when used in combination with other diagnostic tests, Weiner says. But there are potential downsides, too. "There are many concerns: that it could be overused in general, that it could be misused and there will be false diagnoses, both false positives and false negatives," Weiner says. "The medical community is going to have to develop its own standards for how to use it."

MORE FEATURED NEWS >>